Disitamab Vedotin Plus Pembrolizumab in aUC: HER2 Status, Safety and Efficacy Data

Amanda Nizam, MD, from the Cleveland Clinic, interviews Matthew Galsky, MD, from the Tisch Cancer Institute, Mount Sinai School of Medicine, on the global phase 2 trial examining the safety and efficacy of disitamab vedotin plus pembrolizumab in advanced urothelial carcinoma, presented at the European Society for Medical Oncology Congress 2024.

They discuss the importance of HER2 categorization in advanced urothelial carcinoma, the study’s profound data on HER2-low disease treatment, and how the 75% overall response rate in this global trial is the same rate found in the parallel original study conducted in China.